|
|
|
| |
|
|
| |
The latest antibodies news from News Medical |
|
|
|
 | | |
__638886873305831445_multisizecolor_0_custom.jpg) Optimize Antibody Half-Life and Functionality with FcR Products
Assessing antibody half-life through Fc region-FcRn interactions and validating Fc-mediated effector functions like ADCC, ADCP, and CDC are vital for enhancing therapeutic antibodies in oncology. ACRO's FcR collection includes SPR & BLI verified affinity proteins, no-wash FcRn/FcγR binding kits for high-throughput screening, and functional cell lines with stable passage over 20 generations.
| |
|
|
|
|
| | |  Immune checkpoint pathways regulate T cell function and play pivotal roles in the treatment of both cancer and autoimmune diseases. | | | | |  A new microchip invented by Scripps Research scientists can reveal how a person's antibodies interact with viruses-using just a drop of blood. | | | | |  A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment." | | | | |  Chimeric Antigen Receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T cell therapy is the ability of these cells to survive long enough to target the entire tumor. | |
|
|
|
 | | | How would you rate today's newsletter?
| |
|
|
|
|
|
